Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium

AIMS: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome. Our objective was to identify the possible molecular mechanisms of rivaroxaban that contribute to endothelial function. METHODS: Cell...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Álvarez, Ezequiel, Paradela‐Dobarro, Beatriz, Raposeiras‐Roubín, Sergio, González‐Juanatey, José Ramón
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Pharmacodynamics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777430/
https://ncbi.nlm.nih.gov/pubmed/28940408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13440
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller